GeneraMedix Wins Approval for Hypertension Drug
Posted on: Friday, 4 July 2008, 09:00 CDT
GeneraMedix has received approval from the FDA for its Epoprostenol for Injection 1.5mg new drug application.
GeneraMedix's Epoprostenol for Injection 1.5mg is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Ronald Quadrel, president and CEO of GeneraMedix, said: "The addition of Epoprostenol for Injection to our cadre of FDA approved products fits well with our overall objective of providing injectable drugs that are difficult to source or manufacture while providing benefits for patients."
Source: Datamonitor
Related Articles
- GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 Mg
- Teva Obtains Approval for Generic Flolan for Injection
- GeneraMedix Inc. Announces FDA Approval and Launch of Ampicillin and Sulbactam for Injection, USP
- Lawsuits Seek to Ban Lethal Injection
- Intern MD Injects Patient With Olive Oil
- GDC Seeks Cash Injection
- Kerry Says Edwards Injecting 'Enthusiasm'
- Injecting the Fountain of Youth
- The role of the interaction coefficient in the prediction of the fiber orientation in planar injection moldings
User Comments (0)
RSS Feeds